Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Talaris Therapeutics Announces Closing of Initial Public Offering

May 11, 2021
BOSTON and LOUISVILLE, KY - May 11, 2021 - Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of…

Biomea Announces Closing of Initial Public Offering

April 20, 2021
REDWOOD CITY, CA - April 20, 2021 - Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to…

Antios Therapeutics Raises $96 Million in a Series B Financing

April 12, 2021
MENDHAM, N.J. - April 12, 2021  – Antios Therapeutics, Inc. (“Antios”) today announced the successful completion of a $96 million Series B financing. The proceeds from this financing will support…